Chapter 25: Discovery of Memoquin, a Multitarget-Directed Ligand (MTDL) for the Treatment of Alzheimer's Disease Check Access
-
Published:07 May 2010
M. Laura Bolognesi, A. Minarini, and C. Melchiorre, in Emerging Drugs and Targets for Alzheimer's Disease: Volume 2: Neuronal Plasticity, Neuronal Protection and Other Miscellaneous Strategies, ed. A. Martinez and A. Martinez, The Royal Society of Chemistry, 2010, vol. 2, ch. 25, pp. 213-227.
Download citation file:
Alzheimer's disease (AD) is an important neurodegenerative disorder for which no cure exists. It is a complex multifactorial syndrome. This opens up the possibility of achieving disease-modifying therapeutics by identifying ligands that possess a multi-target mechanism of action. Here, we report on memoquin, a novel multifunctional compound designed by inserting the benzoquinone nucleus of coenzyme Q into a polyamine scaffold. Detailed in vitro and in vivo investigations showed that memoquin combats AD on different fronts: it inhibits acetylcholinesterase, amyloid formation and aggregation, and also oxidative damage. These results indicate the potential for the development of multi-targeted drug candidates for the treatment of AD.
